{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.0","value":".4"},{"groupId":"OG001","spread":"1.1","value":".4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"882"},{"groupId":"OG001","value":"884"}],"units":"Participants"}],"description":"To compare the skeletal morbidity rate, defined as the number of skeletal-related events per year, of patients receiving every 12 week dosing to those receiving every 4 week dosing.","dispersionType":"Standard Deviation","groups":[{"description":"Patients receive zoledronic acid IV over at least 15 minutes every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Arm I (Zoledronic Acid Every 4 Weeks)"},{"description":"Patients receive zoledronic acid IV over at least 15 minutes every 12 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"Arm II (Zoledronic Acid Every 12 Weeks)"}],"paramType":"MEAN","populationDescription":"1766 patients were treated and analyzed.","reportingStatus":"POSTED","timeFrame":"from baseline up to 2 years","title":"Skeletal Morbidity Rate","type":"SECONDARY","unitOfMeasure":"SRE's per year"}